Concerns Rise Over Librela: Dog Owners Report Serious Side Effects and Health Deterioration

Pet Owners Report Concerns Over Librela Drug for Dogs

Librela is a new medication for treating arthritis in dogs. Owners report serious side effects after their pets received the drug. Ashley Burden shared her story about her labradoodle, Hudson. He received Librela and initially showed improvements. However, after his third dose, he experienced unusual behavior, lethargy, and eventually died.

Burden is among several dog owners questioning the safety of Librela. A class-action lawsuit from New Jersey claims the drug is linked to thousands of adverse events in dogs, including lethargy, incontinence, and even death. The Globe and Mail interviewed multiple pet owners whose dogs’ health declined following treatment.

Many pet owners assert they were assured Librela had no serious side effects. Others express frustration at not being fully informed about the risks. Librela, along with a similar drug for cats called Solensia, was approved for use in Canada in 2021 by Zoetis Inc. The company insists the drug is safe and has undergone thorough testing.

Monoclonal antibodies like Librela aim to relieve pain in aging pets. This field is becoming increasingly important as pet owners seek better quality of life for their animals. However, reports of severe health declines following treatment have raised alarms.

Veterinarians did not always communicate the potential risks associated with Librela. Roberta Mercier’s dog, Johnny, experienced significant health changes after receiving the drug. She felt regret for not researching more about its effects.

Owners have expressed serious concerns over the lack of thorough information about Librela before injections. They have shared their experiences in online forums, highlighting the importance of being informed.

Health Canada reported a growing number of adverse reaction reports related to Librela. In 2023, 263 reports were received, with an additional 187 in the first half of 2024. However, Health Canada cautions that these figures do not indicate the drug’s overall risk.

Zoetis maintains confidence in Librela’s effectiveness for treating osteoarthritis pain when used as recommended. Yet, some veterinarians believe Librela should only be a last resort for arthritis treatment.

Pet owners like Lynne Cutting have found success with Librela for their dogs, despite the mixed reports. It’s essential for all pet owners to be informed of possible side effects. The continuing growth of pet medications highlights the need for clear communication between veterinarians and pet owners regarding treatment options and their associated risks.

Zoetis has adjusted Librela’s labeling to better inform veterinarians and consumers about reported side effects. However, no regulations currently require veterinarians to provide this information, creating gaps in communication.

Veterinarians are expected to inform pet owners about potential risks, but the current system lacks uniformity. Improved transparency and communication can help owners make informed decisions about their pets’ health and well-being.